ASE values and 95% bootstrap confidence intervals for all estimators under all scenarios. by Mahmut Sami Erdoğan (22097195)

Subjects:

Numerical values underlying all Figs. by Juliana Zimmermann (10507091)

Subjects:

Numeric values used to generate all the graphs presented in the figures. by Wenjia Yu (9422059)

Subjects:

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…<p><b>(A)</b> Top: behavioral timescales do not differ between different groups of participants (exp. 1 and 3/4) doing the same task; Bottom: Illustration of ECoG electrode placement for all subjects for both two location (left) and four location (right) tasks for the frontal, motor and parietal regions. …”

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes by Shakkira Erimban (6882539)

Subjects:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes by Shakkira Erimban (6882539)

Subjects:

An increase in MOI decreases neuronal dendrite numbers. by Emily Z. Tabaie (16630841)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

ActAs and CoT prompt strategies do not result in decreased error rate for tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

Self-correction prompt strategy results in decreased error rate for all tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

fileCont prompt strategy results in decreased error rate for some tasks with increasing complexity. by Jacqueline A. Jansen (14894276)